STOCK TITAN
  1. Home
  2. News
  3. REPL

Replimune Group, Inc. - $REPL STOCK NEWS

Welcome to our dedicated page for Replimune Group news (Ticker: $REPL), a resource for investors and traders seeking the latest updates and insights on Replimune Group stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Replimune Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Replimune Group's position in the market.

News
Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update
Rhea-AI Summary
Replimune Group, Inc. (NASDAQ: REPL) plans to hold a conference call in early December to provide an RP1 skin cancer program update, including topline data from the CERPASS clinical trial of RP1 combined with Libtayo in cutaneous squamous cell carcinoma and initial data from the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.85%
Tags
earnings
-
News
Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Rhea-AI Summary
Replimune Group, Inc. announced updated interim results from the Phase 1/2 clinical trial of RP1 monotherapy for the treatment of skin cancers in patients who have had solid organ or hematopoietic cell transplants. The overall response rate was 34.8%, with 5 complete responses and 3 partial responses. RP1 monotherapy was well tolerated and showed good durability of benefit. This treatment could be a safe and effective option for patients with limited treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Replimune Group grants inducement equity awards to CFO Emily Hill
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.79%
Tags
none
News
Replimune Announces Appointment of Emily Hill as Chief Financial Officer
Rhea-AI Summary
Replimune appoints Emily Hill as CFO, bringing financial planning and strategy expertise. Data from two potentially registrational trials expected soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
management
-
News
Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, Joins Coya’s Board of Directors
Rhea-AI Summary
Coya Therapeutics appoints Dieter Weinand to its board of directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
management
-
News
Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
Rhea-AI Summary
Replimune Group, Inc. provides a business update and announces financial results for Q1 2023. Topline data from the CERPASS clinical trial of RP1 in combination with Libtayo in cutaneous squamous cell carcinoma expected in early Q4 2023. Cost sharing collaboration with Incyte for a clinical trial in CSCC. Positive updates for RP1 and RP2 presented at ASCO. Strong balance sheet with cash runway into H2 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.69%
Tags
earnings
News
Replimune to Present at Two Upcoming Investor Conferences
Rhea-AI Summary
Replimune Group, Inc. (NASDAQ: REPL) Announces Participation in BTIG Virtual Biotechnology Conference 2023 and Wedbush PacGrow Healthcare Conference 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
conferences
-
News
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
Rhea-AI Summary
Replimune Group, Inc. (NASDAQ: REPL) and Incyte (NASDAQ: INCY) announced a clinical trial collaboration and supply agreement to study RP1, Replimune’s lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor. This collaboration aims to explore the use of RP1 in the neoadjuvant setting for cutaneous squamous cell carcinoma (CSCC) and other cancer types. The unique potential of the RPx platform to induce a patient-specific anti-tumor immune response with an off-the-shelf treatment is highlighted, along with the potential to improve patient experience through the combination with Incyte’s oral PD-L1 inhibitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
clinical trial
-
News
Replimune Announces Sander Slootweg will Depart from its Board of Directors
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.44%
Tags
management
News
Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.56%
Tags
clinical trial
Stock REPL logo
Replimune Group, Inc.

Nasdaq:REPL

REPL Rankings

#3137 Ranked by Market Cap
#3660 Ranked by Stock Gains
N/A Ranked by Dividends

REPL Stock Data

426.65M
39.05M
5.8%
113.16%
12.6%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
WOBURN

About REPL

replimune group, inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. it uses its proprietary immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. the company's lead product candidate is rp1, a selectively replicating version of herpes simplex virus 1, which is in phase i/ii clinical trials for a range of solid tumors; and that is in phase ii clinical trials for patients with cutaneous squamous cell carcinoma. it is also developing rp2, which is in phase i clinical trials for an anti-ctla-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by ctla-4; and rp3 to express immune-activating proteins that stimulate t cells. replimune group, inc. was founded in 2015 and is headquartered in woburn, massachusetts.